JPMorgan Chase & Co. 13D and 13G filings for Evolent Health, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-04-09 1:17 pm Sale | 2024-03-29 | 13G | Evolent Health, Inc. EVH | JPMORGAN CHASE & CO JPM | 4,679,353 4.000% | -1,184,177 (-20.20%) | Filing |
| 2024-01-18 08:19 am Purchase | 2023-12-29 | 13G | Evolent Health, Inc. EVH | JPMORGAN CHASE & CO JPM | 5,863,530 5.100% | 494,705 (+9.21%) | Filing |
| 2023-01-20 12:28 pm Sale | 2022-12-30 | 13G | Evolent Health, Inc. EVH | JPMORGAN CHASE & CO JPM | 5,368,825 5.300% | -743,415 (-12.16%) | Filing |
| 2022-01-10 3:02 pm Sale | 2021-12-31 | 13G | Evolent Health, Inc. EVH | JPMORGAN CHASE & CO JPM | 6,112,240 6.800% | -422,295 (-6.46%) | Filing |
| 2021-01-22 10:48 am Purchase | 2020-12-31 | 13G | Evolent Health, Inc. EVH | JPMORGAN CHASE & CO JPM | 6,534,535 7.600% | 219,365 (+3.47%) | Filing |